Berenberg Bank Cuts UCB (OTCMKTS:UCBJY) Price Target to €120.00

UCB (OTCMKTS:UCBJYGet Rating) had its price objective lowered by equities researchers at Berenberg Bank from €122.00 ($127.08) to €120.00 ($125.00) in a research report issued on Friday, The Fly reports. The firm currently has a “buy” rating on the stock.

A number of other brokerages have also weighed in on UCBJY. Deutsche Bank Aktiengesellschaft lowered shares of UCB from a “buy” rating to a “hold” rating in a research report on Monday, January 24th. Morgan Stanley lowered shares of UCB from an “overweight” rating to an “equal weight” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from, the company has an average rating of “Hold” and an average target price of $86.42.

UCB stock traded up $0.74 during mid-day trading on Friday, reaching $46.99. The company had a trading volume of 24,056 shares, compared to its average volume of 23,185. UCB has a fifty-two week low of $44.92 and a fifty-two week high of $63.94. The business has a fifty day simple moving average of $57.06 and a 200 day simple moving average of $55.06.

About UCB (Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Articles

The Fly logo

Analyst Recommendations for UCB (OTCMKTS:UCBJY)

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with's FREE daily email newsletter.